Table: Solasia Pharma -2017 group results (IFRS)

Solasia Pharma KK

09/02/2018 06:30

Feb 9 (Reuters)-  
              Solasia Pharma K. K.  
              CONSOLIDATED FINANCIAL HIGHLIGHTS  
     (in billions of yen unless specified)  
                   Year ended      Year ended       Year to        NEXT   
                Dec 31, 2017    Dec 31, 2016   Dec 31, 2018      YEAR     
                   LATEST         YEAR-AGO        COMPANY      COMPANY    
                   RESULTS         RESULT        FORECAST    H1 FORECAST  
  Sales            410 mln         501 mln                                
                 (-18.0 pct)    (+118.5 pct)                              
  Operating       loss 1.01     loss 462 mln                              
  Pretax          loss 1.02     loss 494 mln                              
  Net             loss 1.01     loss 474 mln                              
  EPS Basic    loss 12.24 yen  loss 18.46 yen                             
  EPS Diluted  loss 12.24 yen  loss 18.46 yen                             
  Ann Div            NIL             NIL            NIL                   
  -Q2 Div            NIL             NIL            NIL                   
  -Q4 Div            NIL             NIL            NIL                   
  
  NOTE - Solasia Pharma K. K..  
  (Figures are reported based on international accounting rules (IFRS).)  
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half  
  dividend and Q4 to the second-half dividend announced before a new corporate law in  
  2006 allowed companies to pay and report dividends on a quarterly basis. 
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4597.T 
  ((Tokyo Headline News Desk +813 6441 1812))